Abstract
Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4 pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4 inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism of CDK4 inhibitors, the structure activity relationships (SARs) of the selective CDK4 inhibitors and the latest developments of the selective CDK4 inhibitors in clinical trials.
Keywords: Anti-cancer agents, cell cycle, clinical trials, cyclin-dependent kinases 4, selective inhibitors, structure activity relationship (SAR).
Anti-Cancer Agents in Medicinal Chemistry
Title:Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Volume: 17 Issue: 5
Author(s): Haixing Guan, Yongli Du*, Weiwei Han, Jingkang Shen*Qunyi Li
Affiliation:
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353,China
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203,China
Keywords: Anti-cancer agents, cell cycle, clinical trials, cyclin-dependent kinases 4, selective inhibitors, structure activity relationship (SAR).
Abstract: Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4 pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4 inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism of CDK4 inhibitors, the structure activity relationships (SARs) of the selective CDK4 inhibitors and the latest developments of the selective CDK4 inhibitors in clinical trials.
Export Options
About this article
Cite this article as:
Guan Haixing, Du Yongli*, Han Weiwei, Shen Jingkang*, Li Qunyi, Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (5) . https://dx.doi.org/10.2174/1871520617666170103095527
DOI https://dx.doi.org/10.2174/1871520617666170103095527 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Flavonoids with Therapeutic Potential in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Current Pharmaceutical Design Mouse Strains for Prostate Tumorigenesis Based on Genes Altered in Human Prostate Cancer
Current Drug Targets Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times
Recent Patents on Biotechnology Epigenetics in Ocular Diseases
Current Genomics New Insights into Binding Interfaces of Coagulation Factors V and VIII and their Homologues - Lessons from High Resolution Crystal Structures
Current Protein & Peptide Science Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Molecular Genetics of Familial Exudative Vitreoretinopathy and Norrie Disease
Current Genomics Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry